Diane is a pharmaceutical industry veteran who is passionate about changing people's lives by helping groundbreaking drugs reach the global market. Previously, Diane served for more than 30 years in various leadership roles in drug development at Pfizer. She has a proven track record of innovative regulatory strategies, including the first approved “virtual” clinical trial. Diane developed and executed regulatory strategies for a broad portfolio of Pfizer’s blockbuster drugs, including Celebrex and Lyrica.
Diane holds a B.S. in Chemical Engineering from MIT and serves as Senior Advisor for MIT's NEW Drug Development ParadIGmS (NEWDIGS) program. She is currently an independent consultant with interests in pediatrics, digital health, personalized medicine and working in the grey space of regulatory science.